Dr. Kubasek has over 25 years of experience in business development, program leadership and alliance management in both industry and academia. Since 2018 he has been Director of Strategic Alliances at the Broad Institute of MIT and Harvard. Previously, he was Vice President of Business Development and Alliance Management at HiFiBiO, an antibody-based drug discovery and development company, where he led the companies partnering and therapeutic evaluation efforts. He was a Vice President at Merrimack Pharmaceuticals where, in collaboration with Sanofi, he led the company’s anti-Her3 program (seribantumab) through five Phase 1 and four Phase 2 biomarker driven clinical studies in several cancer indications. In addition, he played a key role in the companies’ financing and business development activities. He joined Praecis Pharmaceuticals as a start-up scientist and held positions of increasing responsibility in the areas of business development and program management and leadership. At Praecis he led programs through the filing of 2 INDs and several Phase 1 and Phase 2 clinical studies. In addition, he played a major role in Praecis’ fund raising and partnering activities and contributed to the approval of Plenaxis (abarelix) for the treatment of prostate cancer. He has co-authored 22 publications in leading scientific journals and is a co-inventor on 4 issued patents.
Dr. Kubasek received a B.A. in Biochemistry from the University of California at Davis and a Ph.D. in Molecular Biology/Biophysics from the University of Oregon. He was a post-doctoral fellow at the Ludwig–Maximilians-Universität München and at the Massachusetts General Hospital/Harvard Medical School.